Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""lomustine"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 612
Tytuł:
The Development of an Extraction Method for Simultaneously Analyzing Fatty Acids in Macroalgae Using SPE with Derivatization for LC-MS/MS.
Autorzy:
Yum T; Department of Chemistry, Yonsei University, Wonju 26493, Republic of Korea.
Kim EY; Department of Chemistry, Yonsei University, Wonju 26493, Republic of Korea.
Kim Y; Department of Chemistry, Yonsei University, Wonju 26493, Republic of Korea.
Choi S; Department of Chemistry, Yonsei University, Wonju 26493, Republic of Korea.
Paeng KJ; Department of Chemistry, Yonsei University, Wonju 26493, Republic of Korea.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2024 Jan 16; Vol. 29 (2). Date of Electronic Publication: 2024 Jan 16.
Typ publikacji:
Journal Article
MeSH Terms:
Fatty Acids*
Biofuels*
Lomustine/*analogs & derivatives
Chromatography, Liquid ; Liquid Chromatography-Mass Spectrometry ; Tandem Mass Spectrometry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Ganoderma adspersum (Ganodermataceae): Investigation of Its Secondary Metabolites and the Antioxidant, Antimicrobial, and Cytotoxic Potential of Its Extracts.
Autorzy:
Chafouz R; Laboratory of Pharmacognosy, Faculty of Health Sciences, School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Karavergou S; Laboratory of Pharmacognosy, Faculty of Health Sciences, School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Tsiftsoglou OS; Laboratory of Pharmacognosy, Faculty of Health Sciences, School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Maskovic P; Department of Chemistry and Chemical Engineering, Faculty of Agronomy, University of Kragujevac, Cara Dušana 34, 32000 Čačak, Serbia.
Lazari D; Laboratory of Pharmacognosy, Faculty of Health Sciences, School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Dec 30; Vol. 25 (1). Date of Electronic Publication: 2023 Dec 30.
Typ publikacji:
Journal Article
MeSH Terms:
Ganoderma*
Polyporaceae*
Antineoplastic Agents*
Anti-Infective Agents*/pharmacology
Lomustine/*analogs & derivatives
Antioxidants/pharmacology ; Methanol
SCR Organism:
Ganoderma adspersum
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro.
Autorzy:
Fuchs D; Division of Radiation Oncology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.; Center for Clinical Studies, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Rohrer Bley C; Division of Radiation Oncology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.; Center for Clinical Studies, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Morandi L; Department of biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.; Functional and Molecular Neuroimaging Unit, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Tonon C; Department of biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.; Functional and Molecular Neuroimaging Unit, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Weyland MS; ZHAW School of Engineering, Winterthur, Switzerland.
Nytko KJ; Division of Radiation Oncology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.; Center for Clinical Studies, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Pokaż więcej
Źródło:
Veterinary medicine and science [Vet Med Sci] 2023 Jul; Vol. 9 (4), pp. 1573-1583. Date of Electronic Publication: 2023 Jun 26.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Glioma*/veterinary
Glioma*/drug therapy
Dog Diseases*/drug therapy
Animals ; Dogs ; Temozolomide/pharmacology ; Temozolomide/therapeutic use ; Lomustine/therapeutic use ; Lomustine/pharmacology ; Dacarbazine/pharmacology ; Dacarbazine/therapeutic use ; Cell Survival
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma.
Autorzy:
Limmer S; Small Animal Hospital, University of Veterinary Medicine Hannover, Bünteweg 9, Gebäude 280, 30559, Hannover, Germany.
Nerschbach V; Small Animal Hospital, University of Veterinary Medicine Hannover, Bünteweg 9, Gebäude 280, 30559, Hannover, Germany.
Eberle N; Center for Small Animal Medicine, VetSpezial, Im Kornfeld 7, 31275, Lehrte, Germany.
Teske E; Department of Clinical Sciences, Veterinary Faculty, Utrecht University, P.O. Box 80.154, 3508TD, Utrecht, The Netherlands. .
Simon Betz D; Small Animal Hospital, University of Veterinary Medicine Hannover, Bünteweg 9, Gebäude 280, 30559, Hannover, Germany. .; Independent Scientific Writing, Translation & Consultancy Clinical Oncology, Bünteweg 9, Gebäude 280, 30559, Hannover, Germany. .
Pokaż więcej
Źródło:
Acta veterinaria Scandinavica [Acta Vet Scand] 2022 Dec 12; Vol. 64 (1), pp. 36. Date of Electronic Publication: 2022 Dec 12.
Typ publikacji:
Journal Article
MeSH Terms:
Dog Diseases*/pathology
Lymphoma, T-Cell*/drug therapy
Lymphoma, T-Cell*/etiology
Lymphoma, T-Cell*/veterinary
Lymphoma*/drug therapy
Lymphoma*/pathology
Lymphoma*/veterinary
Dogs ; Animals ; Lomustine/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma.
Autorzy:
Lebel E; Faculty of Medicine, The Hebrew University of Jerusalem, Israel.; Hematology department, Hadassah Medical Center, Jerusalem, Israel.
Goldschmidt N; Faculty of Medicine, The Hebrew University of Jerusalem, Israel.; Hematology department, Hadassah Medical Center, Jerusalem, Israel.
Siegal T; Center of Neuro-Oncology, Davidoff Institute of Oncology, Rabin Medical Center, Campus Beilinson, Petach Tikva, Israel.
Lossos A; Faculty of Medicine, The Hebrew University of Jerusalem, Israel.; Gaffin Center of Neuro-Oncology, Hadassah Medical Center, Jerusalem, Israel.
Rosenberg S; Faculty of Medicine, The Hebrew University of Jerusalem, Israel.; Gaffin Center of Neuro-Oncology, Hadassah Medical Center, Jerusalem, Israel.
Makranz C; Faculty of Medicine, The Hebrew University of Jerusalem, Israel.; Gaffin Center of Neuro-Oncology, Hadassah Medical Center, Jerusalem, Israel.
Linetski E; Faculty of Medicine, The Hebrew University of Jerusalem, Israel.; Gaffin Center of Neuro-Oncology, Hadassah Medical Center, Jerusalem, Israel.
Gatt ME; Faculty of Medicine, The Hebrew University of Jerusalem, Israel.; Hematology department, Hadassah Medical Center, Jerusalem, Israel.
Gural A; Faculty of Medicine, The Hebrew University of Jerusalem, Israel.; Hematology department, Hadassah Medical Center, Jerusalem, Israel.
Saban R; Faculty of Medicine, The Hebrew University of Jerusalem, Israel.; Hematology department, Hadassah Medical Center, Jerusalem, Israel.
Lavie D; Faculty of Medicine, The Hebrew University of Jerusalem, Israel.; Hematology department, Hadassah Medical Center, Jerusalem, Israel.
Vainstein V; Faculty of Medicine, The Hebrew University of Jerusalem, Israel.; Hematology department, Hadassah Medical Center, Jerusalem, Israel.
Zimran E; Faculty of Medicine, The Hebrew University of Jerusalem, Israel.; Bone-marrow transplant department, Hadassah medical center, Jerusalem, Israel.
Avni B; Faculty of Medicine, The Hebrew University of Jerusalem, Israel.; Bone-marrow transplant department, Hadassah medical center, Jerusalem, Israel.
Grisaro S; Faculty of Medicine, The Hebrew University of Jerusalem, Israel.; Bone-marrow transplant department, Hadassah medical center, Jerusalem, Israel.
Shaulov A; Faculty of Medicine, The Hebrew University of Jerusalem, Israel.; Hematology department, Hadassah Medical Center, Jerusalem, Israel.
Nachmias B; Faculty of Medicine, The Hebrew University of Jerusalem, Israel.; Hematology department, Hadassah Medical Center, Jerusalem, Israel.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Sep; Vol. 63 (9), pp. 2102-2108. Date of Electronic Publication: 2022 May 02.
Typ publikacji:
Journal Article
MeSH Terms:
Central Nervous System Neoplasms*
Lymphoma*/diagnosis
Lymphoma*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Central Nervous System ; Cytarabine/adverse effects ; Humans ; Lomustine/adverse effects ; Methotrexate/adverse effects ; Middle Aged ; Procarbazine/adverse effects ; Receptors, Thrombopoietin ; Rituximab/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics.
Autorzy:
Beltzig L; Institute of Toxicology, University Medical Center Mainz, Obere Zahlbacher Str. 67, D-55131 Mainz, Germany.
Christmann M; Institute of Toxicology, University Medical Center Mainz, Obere Zahlbacher Str. 67, D-55131 Mainz, Germany.
Kaina B; Institute of Toxicology, University Medical Center Mainz, Obere Zahlbacher Str. 67, D-55131 Mainz, Germany.
Pokaż więcej
Źródło:
Cells [Cells] 2022 Aug 19; Vol. 11 (16). Date of Electronic Publication: 2022 Aug 19.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Curcumin*/pharmacology
Glioblastoma*/metabolism
Artesunate/pharmacology ; Cellular Senescence ; Humans ; Lomustine/pharmacology ; Lomustine/therapeutic use ; NF-kappa B ; Neoplasm Recurrence, Local/drug therapy ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; Senotherapeutics ; Temozolomide/pharmacology ; Temozolomide/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Exploration of biomedical knowledge for recurrent glioblastoma using natural language processing deep learning models.
Autorzy:
Jang BS; Department of Radiation Oncology, Seoul National University Hospital, Seoul, Korea.; Department of Radiation Oncology, College of Medicine, Seoul National University, Seoul, Korea.
Park AJ; Artificial Intelligence Research and Development Laboratory, SELVAS AI Incorporation, Seoul, Korea.
Kim IA; Department of Radiation Oncology, Seoul National University Bundang Hospital, 173 Gumiro, Bundanggu, 13620, Seongnamsi, Kyeonggido, Korea. .; Department of Radiation Oncology, College of Medicine, Seoul National University, Seoul, Korea. .
Pokaż więcej
Źródło:
BMC medical informatics and decision making [BMC Med Inform Decis Mak] 2022 Oct 13; Vol. 22 (1), pp. 267. Date of Electronic Publication: 2022 Oct 13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Deep Learning*
Glioblastoma*/drug therapy
Bevacizumab ; Chronic Disease ; Clinical Trials as Topic ; Humans ; Lomustine ; Natural Language Processing ; Nivolumab ; Temozolomide
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Risk factors associated with the onset of lomustine-induced neutropenia in tumour-bearing dogs.
Autorzy:
Treggiari E; Centro Specialistico Veterinario, Oncology service, Milan, Lombardy, Italy.
Cossu G; Willows Veterinary Centre and Referral Service, Oncology service, Solihull, West Midlands, UK.
Valenti P; Clinica Veterinaria Malpensa, Oncology service, Samarate, Lombardy, Italy.
Taylor A; Royal Veterinary College, Queen Mother Hospital for Animals, Oncology service, Hatfield, Hertfordshire, UK.
Pokaż więcej
Źródło:
Veterinary and comparative oncology [Vet Comp Oncol] 2022 Sep; Vol. 20 (3), pp. 577-586. Date of Electronic Publication: 2022 Mar 11.
Typ publikacji:
Journal Article
MeSH Terms:
Dog Diseases*/chemically induced
Dog Diseases*/drug therapy
Dog Diseases*/pathology
Histiocytic Sarcoma*/drug therapy
Histiocytic Sarcoma*/veterinary
Neoplasms*/drug therapy
Neoplasms*/veterinary
Neutropenia*/chemically induced
Neutropenia*/drug therapy
Neutropenia*/veterinary
Animals ; Anthracyclines ; Antineoplastic Agents, Alkylating/adverse effects ; Dogs ; Lomustine/adverse effects ; Risk Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas.
Autorzy:
Tanis JB; Department of Small Animal Clinical Science, Institute of Veterinary Science, University of Liverpool, Liverpool, UK.
Mason SL; Department of Veterinary Medicine, University of Cambridge, Cambridge, UK.
Maddox TW; Department of Small Animal Clinical Science, Institute of Veterinary Science, University of Liverpool, Liverpool, UK.
Blackwood L; Department of Small Animal Clinical Science, Institute of Veterinary Science, University of Liverpool, Liverpool, UK.
Killick DR; Department of Small Animal Clinical Science, Institute of Veterinary Science, University of Liverpool, Liverpool, UK.
Amores-Fuster I; Department of Small Animal Clinical Science, Institute of Veterinary Science, University of Liverpool, Liverpool, UK.
Harper A; Department of Small Animal Clinical Science, Institute of Veterinary Science, University of Liverpool, Liverpool, UK.
Finotello R; Department of Small Animal Clinical Science, Institute of Veterinary Science, University of Liverpool, Liverpool, UK.
Pokaż więcej
Źródło:
Veterinary and comparative oncology [Vet Comp Oncol] 2018 Sep; Vol. 16 (3), pp. 361-369. Date of Electronic Publication: 2018 Jan 30.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Dog Diseases/*drug therapy
Lomustine/*administration & dosage
Lymphoma, Non-Hodgkin/*veterinary
Prednisolone/*administration & dosage
Procarbazine/*administration & dosage
Animals ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Dogs ; Female ; Lomustine/therapeutic use ; Lymphoma, Non-Hodgkin/drug therapy ; Male ; Neutropenia/chemically induced ; Prednisolone/therapeutic use ; Procarbazine/therapeutic use ; Recurrence ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.
Autorzy:
Wick A; Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Sander A; Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
Koch M; Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Bendszus M; Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany.
Combs S; Department of Radiation Oncology at the Klinikum Rechts der Isar, Technical University Munich, Munich, Germany.
Haut T; Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Dormann A; Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Walter S; Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Pertz M; Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany.
Merkle-Lock J; Coordination Centre for Clinical Trials (KKS), Medical Faculty & University Hospital Heidelberg, Heidelberg, Germany.
Selkrig N; Coordination Centre for Clinical Trials (KKS), Medical Faculty & University Hospital Heidelberg, Heidelberg, Germany.
Limprecht R; Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
Baumann L; Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
Kieser M; Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
Sahm F; Department of Neuropathology, University Hospital Heidelberg, DKTK and CCU Neuropathology, DKFZ, Heidelberg, Germany.
Schlegel U; Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany.
Winkler F; Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany.; German Cancer Consortium (DKTK), Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Platten M; DKTK, Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, DKFZ, Heidelberg, Germany.; Department of Neurology, Medical faculty, MCTN, University of Heidelberg, Mannheim, Germany.
Wick W; Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany. .; German Cancer Consortium (DKTK), Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. .; Neurology Clinic, University of Heidelberg & CCU Neurooncology, DKFZ, Im Neuenheimer Feld 400, D-69120, Heidelberg, Germany. .
Kessler T; Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany.; German Cancer Consortium (DKTK), Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 Jun 13; Vol. 22 (1), pp. 645. Date of Electronic Publication: 2022 Jun 13.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Brain Neoplasms*/drug therapy
Brain Neoplasms*/genetics
Brain Neoplasms*/pathology
Oligodendroglioma*/drug therapy
Oligodendroglioma*/genetics
Oligodendroglioma*/pathology
Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Humans ; Lomustine/therapeutic use ; Neoplasm Grading ; Procarbazine/therapeutic use ; Quality of Life ; Treatment Outcome ; Vincristine/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Outcome in dogs with curative-intent treatment of localized primary pulmonary histiocytic sarcoma.
Autorzy:
Murray CA; William R. Pritchard Veterinary Medical Teaching Hospital, University of California, Davis, California, USA.
Willcox JL; Department of Veterinary Surgical and Radiological Sciences, University of California, Davis, California, USA.
De Mello Souza CH; Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA.
Husbands B; Department of Veterinary and Clinical Sciences, Ohio State University, Columbus, Ohio, USA.
Cook MR; Department of Veterinary and Clinical Sciences, Ohio State University, Columbus, Ohio, USA.
Clifford C; Hope Veterinary Specialists/BluePearl Malvern, Malvern, Pennsylvania, USA.
Leeper H; Department of Clinical Sciences, Oregon State University, Corvallis, Oregon, USA.
Pellin M; Department of Medical Sciences, University of Wisconsin, Madison, Wisconsin, USA.
Richardson D; Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Ontario, USA.
Herrera CL; Boundary Bay Veterinary Specialty Hospital, Langley, British Columbia, Canada.
Krick E; Mount Laurel Animal Hospital, Mount Laurel, New Jersey, USA.
McMillan S; Veterinary Emergency + Referral Center of Hawaii, Honolulu, Hawaii, USA.
Al-Nadaf S; Department of Veterinary Surgical and Radiological Sciences, University of California, Davis, California, USA.
Skorupski KA; Department of Veterinary Surgical and Radiological Sciences, University of California, Davis, California, USA.
Pokaż więcej
Źródło:
Veterinary and comparative oncology [Vet Comp Oncol] 2022 Jun; Vol. 20 (2), pp. 458-464. Date of Electronic Publication: 2021 Dec 19.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Dog Diseases*/drug therapy
Dog Diseases*/pathology
Histiocytic Sarcoma*/drug therapy
Histiocytic Sarcoma*/veterinary
Lung Neoplasms*/drug therapy
Lung Neoplasms*/veterinary
Animals ; Dogs ; Lomustine/therapeutic use ; Lung/pathology ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008-2017).
Autorzy:
Moirano SJ; College of Veterinary Medicine, Cornell University, Ithaca, New York.
Dewey CW; Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York.; Veterinary Specialists and Emergency Services of Rochester, Rochester, NY.; Long Island Veterinary Specialists, Plainview, NY.
Wright KZ; Oncology Service, Animal Medical Center, New York, New York.; Oncology Service, BluePearl Veterinary Partners, Tampa, Florida.
Cohen PW; Neurology Service, Veterinary Medical Center of Long Island, New York, New York.
Pokaż więcej
Źródło:
Veterinary and comparative oncology [Vet Comp Oncol] 2018 Dec; Vol. 16 (4), pp. 459-466. Date of Electronic Publication: 2018 May 24.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Antineoplastic Agents, Alkylating/*therapeutic use
Brain Neoplasms/*veterinary
Dog Diseases/*drug therapy
Glioma/*veterinary
Lomustine/*therapeutic use
Administration, Oral ; Animals ; Antineoplastic Agents, Alkylating/administration & dosage ; Brain Neoplasms/drug therapy ; Brain Neoplasms/mortality ; Dog Diseases/mortality ; Dogs ; Female ; Glioma/drug therapy ; Glioma/mortality ; Lomustine/administration & dosage ; Male ; Retrospective Studies ; Survival Analysis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Canine T cell lymphoma treated with lomustine, vincristine, procarbazine, and prednisolone chemotherapy in 35 dogs.
Autorzy:
Morgan E; Department of Oncology, Animal Referral Hospital Brisbane, Brisbane, Australia.
O'Connell K; Department of Oncology, Animal Referral Hospital Brisbane, Brisbane, Australia.
Thomson M; Department of Oncology, Animal Referral Hospital Brisbane, Brisbane, Australia.
Griffin A; Department of Oncology, Animal Referral Hospital Brisbane, Brisbane, Australia.
Pokaż więcej
Źródło:
Veterinary and comparative oncology [Vet Comp Oncol] 2018 Dec; Vol. 16 (4), pp. 622-629. Date of Electronic Publication: 2018 Aug 16.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Dog Diseases/*drug therapy
Lomustine/*administration & dosage
Lymphoma, T-Cell/*veterinary
Prednisolone/*administration & dosage
Procarbazine/*administration & dosage
Vincristine/*administration & dosage
Animals ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Disease-Free Survival ; Dogs ; Female ; Lomustine/therapeutic use ; Lymphoma, T-Cell/drug therapy ; Male ; Prednisolone/therapeutic use ; Procarbazine/therapeutic use ; Survival Analysis ; Vincristine/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.
Autorzy:
Galldiks N; Department of Neurology, University Hospital Cologne, Josef-Stelzmann St. 9, 50937, Cologne, Germany. .; Institute of Neuroscience and Medicine (INM-3, -4), Forschungszentrum Juelich, Leo-Brandt-St. 5, 52425, Juelich, Germany. .; Center of Integrated Oncology (CIO), Universities of Cologne and Bonn, Cologne, Germany. .
Dunkl V; Department of Neurology, University Hospital Cologne, Josef-Stelzmann St. 9, 50937, Cologne, Germany.
Ceccon G; Department of Neurology, University Hospital Cologne, Josef-Stelzmann St. 9, 50937, Cologne, Germany.
Tscherpel C; Department of Neurology, University Hospital Cologne, Josef-Stelzmann St. 9, 50937, Cologne, Germany.; Institute of Neuroscience and Medicine (INM-3, -4), Forschungszentrum Juelich, Leo-Brandt-St. 5, 52425, Juelich, Germany.
Stoffels G; Institute of Neuroscience and Medicine (INM-3, -4), Forschungszentrum Juelich, Leo-Brandt-St. 5, 52425, Juelich, Germany.
Law I; Department of Clinical Physiology, Nuclear Medicine & PET, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Henriksen OM; Department of Clinical Physiology, Nuclear Medicine & PET, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Muhic A; Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Poulsen HS; Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Steger J; Department of Neurology, University Hospital Cologne, Josef-Stelzmann St. 9, 50937, Cologne, Germany.
Bauer EK; Department of Neurology, University Hospital Cologne, Josef-Stelzmann St. 9, 50937, Cologne, Germany.
Lohmann P; Institute of Neuroscience and Medicine (INM-3, -4), Forschungszentrum Juelich, Leo-Brandt-St. 5, 52425, Juelich, Germany.
Schmidt M; Dept. of Nuclear Medicine, University Hospital Cologne, Cologne, Germany.
Shah NJ; Institute of Neuroscience and Medicine (INM-3, -4), Forschungszentrum Juelich, Leo-Brandt-St. 5, 52425, Juelich, Germany.; Department of Neurology, University Hospital Aachen, Aachen, Germany.
Fink GR; Department of Neurology, University Hospital Cologne, Josef-Stelzmann St. 9, 50937, Cologne, Germany.; Institute of Neuroscience and Medicine (INM-3, -4), Forschungszentrum Juelich, Leo-Brandt-St. 5, 52425, Juelich, Germany.
Langen KJ; Institute of Neuroscience and Medicine (INM-3, -4), Forschungszentrum Juelich, Leo-Brandt-St. 5, 52425, Juelich, Germany.; Department of Nuclear Medicine, University Hospital Aachen, Aachen, Germany.
Pokaż więcej
Źródło:
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2018 Dec; Vol. 45 (13), pp. 2377-2386. Date of Electronic Publication: 2018 Jul 07.
Typ publikacji:
Clinical Trial; Comparative Study; Journal Article
MeSH Terms:
Magnetic Resonance Imaging*
Positron-Emission Tomography*
Bevacizumab/*therapeutic use
Glioblastoma/*diagnostic imaging
Glioblastoma/*drug therapy
Lomustine/*therapeutic use
Tyrosine/*analogs & derivatives
Adult ; Aged ; Bevacizumab/adverse effects ; Disease Progression ; Drug Interactions ; Female ; Humans ; Lomustine/adverse effects ; Male ; Middle Aged ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Prognostic indicators for naïve canine non-indolent T-cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy.
Autorzy:
Blaxill J; University of Sydney Veterinary Teaching Hospital, Sydney, New South Wales, Australia.
Buzzacott P; School of Nursing, Curtin University, Bentley, Western Australia, Australia.
Finlay J; Perth Veterinary Specialists, Osborne Park, Western Australia, Australia.
Pokaż więcej
Źródło:
Veterinary and comparative oncology [Vet Comp Oncol] 2022 Mar; Vol. 20 (1), pp. 215-226. Date of Electronic Publication: 2021 Sep 23.
Typ publikacji:
Journal Article
MeSH Terms:
Dog Diseases*/drug therapy
Dog Diseases*/mortality
Hypercalcemia*/drug therapy
Hypercalcemia*/veterinary
Lymphoma*/veterinary
Lymphoma, T-Cell*/drug therapy
Lymphoma, T-Cell*/mortality
Lymphoma, T-Cell*/veterinary
Animals ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Dogs ; Lomustine/therapeutic use ; Prednisolone/therapeutic use ; Procarbazine/therapeutic use ; Prognosis ; Retrospective Studies ; T-Lymphocytes ; Vincristine/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Lomustine Incorporated Lipid Nanostructures Demonstrated Preferential Anticancer Properties in C6 Glioma Cell Lines with Enhanced Pharmacokinetic Profile in Mice.
Autorzy:
Satapathy BS; Centurion University of Technology and Management, odisha, India. .
Kumar LA
Pattnaik G
Barik B
Pokaż więcej
Źródło:
Acta chimica Slovenica [Acta Chim Slov] 2021 Dec 15; Vol. 68 (4), pp. 970-982. Date of Electronic Publication: 2021 Dec 15.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents/*chemistry
Lipids/*chemistry
Lomustine/*chemistry
Nanostructures/*chemistry
Animals ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Agents/pharmacology ; Biocompatible Materials/chemistry ; Biocompatible Materials/pharmacology ; Brain/drug effects ; Brain/metabolism ; Cell Line, Tumor ; Cell Survival/drug effects ; Drug Liberation ; Female ; Glioma/metabolism ; Glioma/pathology ; Half-Life ; Hemolysis/drug effects ; Kinetics ; Male ; Mice ; Nanostructures/toxicity
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
Autorzy:
Capper D; Department of Neuropathology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. .
von Deimling A; Department of Neuropathology, University Hospital Heidelberg and Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. .
Brandes AA; Medical Oncology Department, Bellaria-Maggiore Hospitals, Azienda USL-IRCCS Institute of Neurological Sciences, 40139 Bologna, Italy. .
Carpentier AF; Assistance Publique-Hôpitaux de Paris (AP-HP) & Paris 13 University, Hôpital Avicenne, Service de Neurologie, 93009 Bobigny, France. .
Kesari S; UC San Diego Health System, La Jolla, CA 92103, USA. .
Sepulveda-Sanchez JM; Hospital Universitario 12 de Octubre, 28041 Madrid, Spain. .
Wheeler HR; Department of Oncology, Royal North Shore Hospital, St. Leonards, NSW 2065, Australia. .
Chinot O; CHU Hôpital De La Timone, Rue Saint Pierre, 13385 Marseille, France. .
Cher L; Austin Hospital, Heidelberg, VIC 3084, Australia. .
Steinbach JP; Dr. Senckenberg Institute of Neurooncology, University Hospital Frankfurt, 60590 Frankfurt, Germany. .
Specenier P; Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium. .
Rodon J; Medical Oncology, Vall d'Hebron University Hospital, Calle Natzaret, 115-117, 08035 Barcelona, Spain. .
Cleverly A; Eli Lilly and Company, Erl Wood Manor, Windlesham GU20 6PH, UK. cleverly_ann_.
Smith C; Eli Lilly and Company, Erl Wood Manor, Windlesham GU20 6PH, UK. .
Gueorguieva I; Eli Lilly and Company, Erl Wood Manor, Windlesham GU20 6PH, UK. gueorguieva_.
Miles C; Eli Lilly and Company, Erl Wood Manor, Windlesham GU20 6PH, UK. miles_colin_.
Guba SC; Eli Lilly and Company, Indianapolis, IN 46285, USA. guba_susan_.
Desaiah D; Eli Lilly and Company, Indianapolis, IN 46285, USA. desaiah_.
Estrem ST; Eli Lilly and Company, Indianapolis, IN 46285, USA. estrem_shawn_.
Lahn MM; Eli Lilly and Company, Indianapolis, IN 46285, USA. .
Wick W; Department of Neurology, University Hospital Heidelberg, 69120 Heidelberg, Germany. .
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2017 May 06; Vol. 18 (5). Date of Electronic Publication: 2017 May 06.
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Biomarkers, Tumor/*metabolism
Glioblastoma/*drug therapy
Lomustine/*administration & dosage
Neoplasm Recurrence, Local/*drug therapy
Pyrazoles/*administration & dosage
Quinolines/*administration & dosage
Adult ; Antineoplastic Combined Chemotherapy Protocols ; Biomarkers, Tumor/blood ; CD4-CD8 Ratio ; Cytokines/blood ; Female ; Forkhead Transcription Factors/blood ; Forkhead Transcription Factors/metabolism ; Glioblastoma/blood ; Glioblastoma/pathology ; Humans ; Isocitrate Dehydrogenase/metabolism ; Lomustine/adverse effects ; Lomustine/therapeutic use ; Male ; Neoplasm Recurrence, Local/blood ; Neoplasm Recurrence, Local/pathology ; Pyrazoles/adverse effects ; Pyrazoles/therapeutic use ; Quinolines/adverse effects ; Quinolines/therapeutic use ; Smad2 Protein/metabolism ; Survival Analysis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Retrospective evaluation of nimustine use in the treatment of feline lymphoma.
Autorzy:
Sakai K; Veterinary Medical Centre, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Osaka, Japan.
Hatoya S; Veterinary Medical Centre, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Osaka, Japan.
Furuya M; Veterinary Medical Centre, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Osaka, Japan.
Nabetani T; Veterinary Medical Centre, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Osaka, Japan.
Kanegi R; Veterinary Medical Centre, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Osaka, Japan.
Shimamura S; Veterinary Medical Centre, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Osaka, Japan.
Tani H; Veterinary Medical Centre, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Osaka, Japan.
Shimada T; Veterinary Medical Centre, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Osaka, Japan.
Pokaż więcej
Źródło:
Veterinary medicine and science [Vet Med Sci] 2022 Jan; Vol. 8 (1), pp. 3-8. Date of Electronic Publication: 2021 Oct 02.
Typ publikacji:
Case Reports
MeSH Terms:
Cat Diseases*/chemically induced
Cat Diseases*/drug therapy
Lymphoma*/drug therapy
Lymphoma*/veterinary
Animals ; Cats ; Lomustine/adverse effects ; Nimustine/therapeutic use ; Retrospective Studies ; Treatment Outcome
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Viability fingerprint of glioblastoma cell lines: roles of mitotic, proliferative, and epigenetic targets.
Autorzy:
Lavogina D; Institute of Clinical Medicine, University of Tartu, L. Puusepa 8, 50406, Tartu, Estonia. .; Institute of Chemistry, University of Tartu, Tartu, Estonia. .
Laasfeld T; Institute of Chemistry, University of Tartu, Tartu, Estonia.; Department of Computer Science, University of Tartu, Tartu, Estonia.
Vardja M; Department of Radiotherapy and Oncological Therapy, Tartu University Hospital, Tartu, Estonia.
Lust H; Institute of Clinical Medicine, University of Tartu, L. Puusepa 8, 50406, Tartu, Estonia.
Jaal J; Institute of Clinical Medicine, University of Tartu, L. Puusepa 8, 50406, Tartu, Estonia. .; Department of Radiotherapy and Oncological Therapy, Tartu University Hospital, Tartu, Estonia. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Oct 13; Vol. 11 (1), pp. 20338. Date of Electronic Publication: 2021 Oct 13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Brain Neoplasms*/drug therapy
Brain Neoplasms*/genetics
Brain Neoplasms*/metabolism
Glioblastoma*/drug therapy
Glioblastoma*/genetics
Glioblastoma*/metabolism
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Cell Cycle/*drug effects
Epigenesis, Genetic/*drug effects
Gene Expression Regulation, Neoplastic/*drug effects
Azacitidine/pharmacology ; Cell Line, Tumor ; Humans ; Lomustine/pharmacology ; Temozolomide/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
Autorzy:
Keogh RJ; Department of Medical Oncology, Beaumont Hospital, Dublin 9, Ireland.
Aslam R; Department of Medical Oncology, Beaumont Hospital, Dublin 9, Ireland.
Hennessy MA; Department of Medical Oncology, Beaumont Hospital, Dublin 9, Ireland.
Coyne Z; Department of Medical Oncology, Beaumont Hospital, Dublin 9, Ireland.
Hennessy BT; Department of Medical Oncology, Beaumont Hospital, Dublin 9, Ireland.; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin 9, Ireland.; Royal College of Surgeons Ireland, Dublin, Ireland.
Breathnach OS; Department of Medical Oncology, Beaumont Hospital, Dublin 9, Ireland.; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin 9, Ireland.; Royal College of Surgeons Ireland, Dublin, Ireland.
Grogan L; Department of Medical Oncology, Beaumont Hospital, Dublin 9, Ireland.; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin 9, Ireland.; Royal College of Surgeons Ireland, Dublin, Ireland.
Morris PG; Department of Medical Oncology, Beaumont Hospital, Dublin 9, Ireland. .; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin 9, Ireland. .; Royal College of Surgeons Ireland, Dublin, Ireland. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2021 Feb 08; Vol. 21 (1), pp. 140. Date of Electronic Publication: 2021 Feb 08.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Brain Neoplasms/*drug therapy
Drug-Related Side Effects and Adverse Reactions/*epidemiology
Glioma/*drug therapy
Adult ; Brain Neoplasms/pathology ; Drug-Related Side Effects and Adverse Reactions/etiology ; Female ; Follow-Up Studies ; Glioma/pathology ; Humans ; Incidence ; Ireland/epidemiology ; Lomustine/administration & dosage ; Male ; Neoplasm Grading ; Procarbazine/administration & dosage ; Retrospective Studies ; Time Factors ; Vincristine/administration & dosage
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 612

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies